论文部分内容阅读
目的：进一步研究树突状细胞与肿瘤细胞的融合瘤苗细胞主动免疫诱导体内抗肿瘤免疫反应及对荷瘤小鼠的免疫治疗效果。方法：直接分离骨髓树突状细胞和体外生长因子诱导扩增培养相结合，获得大量高纯度的树突状细胞，再以５００ｇ／ＬＰＥＧ诱导其与ＮＳ１骨髓细胞融合，ＨＡＴ选择培养得到两者的融合细胞，体外进行混合淋巴细胞培养，并进行免疫预防与治疗的在体动物实验。结果：融合细胞也能诱导淋巴细胞的增殖反应，而ＮＳ１无此作用。体内免疫预防试验表明，融合细胞活瘤苗１次免疫后，诱导出较强的细胞毒性Ｔ淋巴细胞（ＣＴＬ），并获得抵抗野生型ＮＳ１攻击的保护性反应，但对无关瘤株则无此抵抗力。融合细胞对荷瘤小鼠的免疫治疗试验显示，融合细胞静脉注射后，能够明显抑制肿瘤生长，延长其生存期。结论：树突状细胞与肿瘤细胞融合后的瘤苗体内免疫，能有效地诱导抗肿瘤免疫反应，可望成为肿瘤免疫预防和免疫治疗的新途径。
OBJECTIVE: To further study the anti-tumor immune response in vivo and the immunotherapy effect on the tumor-bearing mice induced by the active immunity of fusion tumor cell of dendritic cells and tumor cells. Methods: Direct dendritic cells were isolated from bone marrow cells in vitro and induced by growth factor-induced expansion of a large number of high purity dendritic cells, and then 500g / LPEG induction with NS1 bone marrow cells fusion, HAT choose culture both Fusion of cells, mixed lymphocyte culture in vitro, and immunological prophylaxis and treatment of in vivo animal experiments. Results: The fusion cells also induced lymphocyte proliferation, but NS1 did not. In vivo immunoprophylaxis experiments showed that after a single immunization with fused cell live tumor vaccine, strong cytotoxic T lymphocytes (CTLs) were induced and a protective response against wild-type NS1 challenge was obtained, but not for unrelated tumor-bearing strains resistance. Immunotherapy of tumor-bearing mice with fusion cells showed that the fusion cells could significantly inhibit tumor growth and prolong their survival after intravenous injection. CONCLUSION: Immunization of tumor inoculation with dendritic cells and tumor cells in vivo can effectively induce anti-tumor immune response and is expected to become a new approach for immunological prevention and immunotherapy.